Evaluating The CURB-65 Score for Prognostic Assessment in COVID-19 Patients: A Systematic Review
DOI:
https://doi.org/10.25170/juhr.v3i2.6640Keywords:
COVID-19, CURB-65, Mortality, PrognosticAbstract
Introduction: Several instruments and biomarkers have been used to assess the severity and predict outcomes in COVID-19 patients, each with varying sensitivity levels. One such tool is the CURB-65 score—an acronym for Confusion, Urea nitrogen, Respiratory rate, Blood pressure, and age ≥65 years—which has traditionally been used to evaluate the severity of community-acquired pneumonia. Its application in COVID-19 patients aims to identify clinical deterioration and assist in risk stratification. Accurate prognosis is essential to guide clinical management and reduce mortality. However, the utility of the CURB-65 score in predicting outcomes in COVID-19 patients remains a subject of debate. This study aims to evaluate the performance of the CURB-65 score in determining the prognosis of patients with COVID-19.
Methods:This systematic review was conducted in accordance with PRISMA guidelines. Relevant studies published between 2020 and 2022 were identified through searches using predefined keywords in PubMed, ScienceDirect, and EBSCO databases. Studies of all designs that assessed the CURB-65 score concerning COVID-19 outcomes were considered for inclusion.
Results: Ten studies were included in this review, evaluating the CURB-65 score's effectiveness in predicting various outcomes in COVID-19 patients, including overall mortality, 30-day mortality, adverse outcomes, need for organ support, ICU admission and intervention, critical illness, mechanical ventilation, and 72-hour mortality. Seven out of ten studies demonstrated good prognostic performance of the CURB-65 score, with sensitivity greater than 80% or an Area Under the Curve (AUC) exceeding 0.80 for predicting mortality.
Conclusion: The CURB-65 score shows promising utility in predicting mortality among COVID-19 patients and may perform better than several other prognostic tools. Its simplicity and accessibility make it a valuable aid in clinical decision-making, although further validation in different populations may be warranted.
References
1.Capraru ID, Vulcanescu DD, Bagiu IC, Horhat FG, Popescu IM, Baditoiu LM, et al. COVID-19 Biomarkers Comparison: Children, Adults and Elders. Medicina (Kaunas). 2023 May 3;59(5):877.
2. Jones BE, Jones J, Bewick T, Lim WS, Aronsky D, Brown SM, et al. CURB-65 pneumonia severity assessment adapted for electronic decision support. Chest. 2011 Jul;140(1):156–63.
3. Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One. 2020;15(11):e0241955.
4. Anurag A, Preetam M. Validation of PSI/PORT, CURB-65 and SCAP scoring system in COVID-19 pneumonia for prediction of disease severity and 14-day mortality. Clin Respir J. 2021 May;15(5):467–71.
5. Armiñanzas C, de Las Revillas FA, Cuadra MG, Arnaiz A, Sampedro MF, González-Rico C, et al. Usefulness of the COVID-GRAM and CURB-65 scores for predicting severity in patients with COVID-19. International Journal of Infectious Diseases. 2021;108:282–8.
6. Bradley J, Sbaih N, Chandler TR, Furmanek S, Ramirez JA, Cavallazzi R. Pneumonia severity index and CURB-65 score are good predictors of mortality in hospitalized patients with SARS-CoV-2 community-acquired pneumonia. Chest. 2022;161(4):927–36.
7. Satici C, Demirkol MA, Sargin Altunok E, Gursoy B, Alkan M, Kamat S, et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. Int J Infect Dis. 2020 Sep;98:84–9.
8. Doğanay F, Ak R. Performance of the CURB-65, ISARIC-4C and COVID-GRAM scores in terms of severity for COVID-19 patients. International Journal of Clinical Practice. 2021;75(10):e14759.
9. Thomas B, Goodacre S, Lee E, Sutton L, Bursnall M, Loban A, et al. Prognostic accuracy of emergency department triage tools for adults with suspected COVID-19: the PRIEST observational cohort study. Emerg Med J. 2021 Aug;38(8):587–93.
10. Artero A, Madrazo M, Fernández-Garcés M, Muiño Miguez A, González García A, Crestelo Vieitez A, et al. Severity Scores in COVID-19 Pneumonia: a Multicenter, Retrospective, Cohort Study. J GEN INTERN MED. 2021 May;36(5):1338–45.
11. Fan G, Tu C, Zhou F, Liu Z, Wang Y, Song B, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 Sep;56(3):2002113.
12. Elmoheen A, Abdelhafez I, Salem W, Bahgat M, Elkandow A, Tarig A, et al. External validation and recalibration of the CURB-65 and PSI for predicting 30-day mortality and critical care intervention in multiethnic patients with COVID-19. International Journal of Infectious Diseases. 2021;111:108–16.
13. Bradley P, Frost F, Tharmaratnam K, Wootton DG, Ahmad M, Aigbirior J, et al. Utility of established prognostic scores in COVID-19 hospital admissions: multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA. BMJ open respiratory research [Internet]. 2020 [cited 2025 Apr 10];7(1). Available from: https://bmjopenrespres.bmj.com/content/7/1/e000729
14. Neto FL, Marino LO, Torres A, Cilloniz C, Marchini JFM, de Alencar JCG, et al. Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. Clinical Microbiology and Infection. 2021;27(7):1037-e1.
15. Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Critical Reviews in Clinical Laboratory Sciences. 2020 Aug 17;57(6):365–88.
16. Shi Y, Wang G, Cai X peng, Deng J wen, Zheng L, Zhu H hong, et al. An overview of COVID-19. Journal of Zhejiang University Science B. 2020;21(5):343.
17. Rod JE, Oviedo-Trespalacios O, Cortes-Ramirez J. A brief-review of the risk factors for covid-19 severity. Revista de saude publica. 2020;54:60.
18. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021 Feb;49(1):15–28.
19. Guo J, Zhou B, Zhu M, Yuan Y, Wang Q, Zhou H, et al. CURB-65 may serve as a useful prognostic marker in COVID-19 patients within Wuhan, China: a retrospective cohort study. Epidemiol Infect. 2020 Oct 1;148:e241.
20. Carriel J, Muñoz-Jaramillo R, Bolaños-Ladinez O, Heredia-Villacreses F, Menéndez-Sanchón J, Martin-Delgado J, et al. CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study. Rev Clin Esp (Barc). 2022 Jan;222(1):37–41.
21. Demir MC, Ilhan B. Performance of the Pandemic Medical Early Warning Score (PMEWS), Simple Triage Scoring System (STSS) and Confusion, Uremia,
Respiratory rate, Blood pressure and age ≥ 65 (CURB-65) score among patients with COVID-19 pneumonia in an emergency department triage setting: a retrospective study. Sao Paulo Med J. 2021 Mar 3;139(2):170–7.
22. Chen J, Liu B, Du H, Lin H, Chen C, Rao S, et al. Performance of CURB-65, PSI, and APACHE-II for predicting COVID-19 pneumonia severity and mortality. Eur J Inflamm. 2021 Jan 1;19:20587392211027083.
23. Butt I, Ochoa-Ferraro A, Dawson C, Madathil S, Gautam N, Sawlani V, et al. Acute confusion as an initial presentation of SARS-CoV-2 infection. Journal of clinical neurology (Seoul, Korea). 2021;17(3):363.
24. García Clemente MM, Herrero Huertas J, Fernández Fernández A, De La Escosura Muñoz C, Enríquez Rodríguez AI, Pérez Martínez L, et al. Assessment of risk scores in Covid‐19. Int J Clinical Practice [Internet]. 2021 Dec [cited 2025 Apr 10];75(12). Available from: https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13705
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Yunisa Astiarani, Gabriella Aninda Puspita Sari, Kevin Kristian
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
